Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 11, 2014, Pages 1424-1430

  Carrascosa, J M ^a   van Doorn, M B A ^b   Lahfa, M ^c   Nestle, F O ^d   Jullien, D ^e,f   Prinz, J C ^g  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SERVICE DE PNEUMOLOGIE   (France)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UNIVERSITÉ LYON 1   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; BRODALUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; IXEKIZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SECUKINUMAB; USTEKINUMAB;

ANTIBODY BLOOD LEVEL; ANTIGEN ANTIBODY COMPLEX; BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; REMISSION; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 85006508365     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12549     Document Type: Review

References (60)

1. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165–178.
2. Christophers E, Segaert S, Milligan G, Molta CT, Boggs R. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat 2013; 24: 193–198.
3. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21: 211–215.
4. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24: 1720–1740.
5. Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739–1745.
6. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460–1468.
7. Remicade Summary of product characteristics 17/05/ 2013.
8. Jullien D. Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis. Ann Dermatol Venereol 2012; 139(Suppl 2): S58–67.
9. van Schouwenburg PA, van de Stadt LA, de Jong RN et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72: 104–109.
10. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418–426.
11. Ducourau E, Mulleman D, Paintaud G et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011; 13: R105.
12. Plasencia C, Pascual-Salcedo D, Nuño L et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012; 71: 1955–1960.
13. Stelara Summary of product characteristics 07/03/ 2013.
14. Zhu Y, Shankar G, Yeilding N, Szapary P, Zhou H, Davis HM. Immunogenicity assessment of ustekinumab in Phase 3 studies in patients with moderate to severe plaque psoriasis. 19th Annual Congress of the European Academy of Dermatology and Venereology, Gothenburg 2010: P563. (Abstr)
15. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719–726.
16. van der Laken CJ, Voskuyl AE, Roos JC et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66: 253–256.
17. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha-receptor: Fc fusion protein. Arch Dermatol 2001; 137: 893–899.
18. Bavbek S, Aydın O, Ataman S, Cahill K, Castells M. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011; 66: 1256–1257.
19. Batycka-Baran A, Flaig M, Molin S, Ruzicka T, Prinz JC. Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. Expert Opin Drug Saf 2012; 11: 911–921.
20. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London: EMEA; 2007. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf)
21. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012; 71: 1914–1915.
22. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumour necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008; 20: 431–435.
23. Hart MH, de Vrieze H, Wouters D et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011; 372: 196–203.
24. Lallemand C, Kavrochorianou N, Steenholdt C et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. J Immunol Methods 2011; 373: 229–239.
25. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362: 82–88.
26. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534–542.
27. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.
28. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–1374.
29. Adisen E, Aral A, Aybay C, Gürer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J Dermatol 2010; 37: 708–713.
30. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106–115.
31. Papp K, Crowley J, Ortonne JP et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434–441.
32. Lecluse LL, Driessen RJ, Spuls PI et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127–132.
33. Menting S, Lumig PV, Vries A-CD et al. Antibody formation to adalimumab in the treatment of psoriasis vulgaris is most often seen before 24 weeks of treatment and has great influence on clinical efficacy: one year data in 59 patients. J Eur Acad Dermatol Venereol 2013; 27(Suppl 4): 1. Abstract P001.
34. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol 2013; 40: 39–42.
35. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–2022.
36. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304–1312.
37. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29–35.
38. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double- blind, placebo- controlled trial (PHOENIX 1). Lancet 2008; 371: 1665–1674.
39. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 52- week results from a randomised, double- blind, placebo- controlled trial (PHOENIX 2). Lancet 2008; 371: 1675–1684.
40. Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118–128.
41. Reich K, Ortonne JP, Gottlieb AB et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012; 167: 180–190.
42. Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181–1189.
43. Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412–421.
44. Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402–411.
45. Kavanaugh A, McInnes IB, Mease PJ et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013; 72: 1777–1785.
46. Nast A, Boehncke WH, Mrowietz U et al. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10(Suppl 2): S1–95.
47. Puig L, Carrascosa JM, Carretero G et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Actas Dermosifiliogr 2013; 104: 694–709.
48. Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol 2012; 92: 362–364.
49. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011; 25: 549–567.
50. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. Am Acad Dermatol 1999; 41: 51–59.
51. Noiles K, Vender R. Biologic survival. J Drugs Dermatol 2009; 8: 329–33.
52. Esposito M, Gisondi P, Cassano N et al. Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study [published online May 6, 2013]. Br J Dermatol 2013; 169: 666–672.
53. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091–1096.
54. Mehren CR, Gniadecki R. Dose-creep of Infliximab during psoriasis treatment: an observational study. Acta Derm Venereol 2012; 92: 355–357.
55. Reich K, Griffiths C, Barker J et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008; 217: 268–275.
56. Gordon KB, Gottlieb AB, Leonardi CL et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9–17.
57. Ortonne J-P, Griffiths C, Daudén E et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev Dermatol 2008; 3: 657–665.
58. Jamnitski A, Bartelds GM, Nurmohamed MT et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284–288.
59. Barker J, Horn EJ, Lebwohl M et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011; 25: 758–764.
60. Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2013. doi:10.1136/annrheumdis-2013-203296 [Epub ahead of print].